Remove en firm legal
article thumbnail

Fifth Circuit Abandons “Ultimate Employment Decisions” As Requirement for Title VII Claims, Holds That Any Discrimination in Terms and Conditions of Employment Is Potentially Actionable

Hall Render

This argument prevailed at the trial court and before a three-judge panel of the Fifth Circuit, but was then rejected by the en banc Fifth Circuit, finding that a less favorable scheduling system where female officers never received full weekends off was a term, condition or privilege of employment within the plain language of Title VII.

40
article thumbnail

50-State Survey of State Court Decisions Supporting Expert-Related Judicial Gatekeeping

Drug & Device Law

W]hether a witness is qualified to render an opinion as an expert is a legal determination for the trial court and will not be disturbed absent a manifest abuse of discretion. Those are not credibility determinations that are the province of the jury, but rather legal determinations about the reliability of the expert’s methodology.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

We Said It Before; We’ll Say It Again – Drug/Device Companies Should Join PLAC

Drug & Device Law

The defendant first sought PLAC’s help on en banc rehearing, after suffering a loss on admission of expert testimony that we considered to be the worst decision of 2021. It is yet another way that PLAC’s organizational resources can help drug, device, and vaccine companies address legal issues of mutual concern. 19-2899 (8th Cir.

FDA 59
article thumbnail

Plaintiff MDL Censuses – Probably Worse Than Nothing

Drug & Device Law

However, since census registrants have never actually filed suit, their “dismissal” has no legal effect beyond the statute of limitations no longer being tolled. Counsel must submit an ICF for all individuals who signed a retainer agreement with the leadership applicant’s firm before April 1, 2020. In re Juul Labs , 2019 U.S.

59
article thumbnail

Express Preemption Based On Forceful Agency Action Pursuant To Law

Drug & Device Law

When we have given talks on preemption, whether to law firm personnel, attendees of professional conferences, or new FDA employees, we have tended to start with the Supremacy Clause and then break up the types of preemption and the issues related to them into different buckets. Impossibility is not part of the analysis of express preemption.

FDA 52